

Relevance of the C-5 Position to Schweinfurthin Induced Cytotoxicity

Joseph J. Topczewski,^a Michael P. Callahan,^a John G. Kodet,^a Jerry D. Inbarasu,^a Nolan R.

Mente,^a John A. Beutler,^b and David F. Wiemer^{a,*}

^a *Department of Chemistry, University of Iowa, Iowa City, IA 52242-1294, USA*


^b *Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA*

Supplemental Table of Contents



| | |
|--|-----|
| ¹ H NMR for compound 8 (300 MHz) | S4 |
| ¹³ C NMR for compound 8 (75 MHz) | S5 |
| ¹ H NMR for compound 9 (300 MHz) | S6 |
| ¹³ C NMR for compound 9 (75 MHz) | S7 |
| ¹ H NMR for compound 10 (300 MHz) | S8 |
| ¹³ C NMR for compound 10 (75 MHz) | S9 |
| ¹ H NMR for compound 11 (300 MHz) | S10 |
| ¹³ C NMR for compound 11 (75 MHz) | S11 |
| ¹ H NMR for compound 13 (300 MHz) | S12 |
| ¹³ C NMR for compound 13 (75 MHz) | S13 |
| ¹ H NMR for compound 14 (300 MHz) | S14 |
| ¹³ C NMR for compound 14 (75 MHz) | S15 |
| ¹ H NMR for compound 18 (400 MHz) | S16 |
| ¹³ C NMR for compound 18 (100 MHz) | S17 |
| ¹ H NMR for compound 20 (300 MHz) | S18 |
| ¹³ C NMR for compound 20 (75 MHz) | S19 |
| ¹ H NMR for compound 21 (400 MHz) | S20 |
| ¹³ C NMR for compound 21 (100 MHz) | S21 |
| ¹ H NMR for compound 22 (300 MHz) | S22 |
| ¹³ C NMR for compound 22 (75 MHz) | S23 |
| ¹ H NMR for compound 23 (400 MHz) | S24 |
| ¹³ C NMR for compound 23 (100 MHz) | S25 |
| ¹ H NMR for compound 24 (400 MHz) | S26 |
| ¹³ C NMR for compound 24 (100 MHz) | S27 |

| | |
|--|-----|
| ¹ H NMR for compound 25 (400 MHz) | S28 |
| ¹³ C NMR for compound 25 (100 MHz) | S29 |
| ¹ H NMR for compound 27 (300 MHz) | S30 |
| ¹³ C NMR for compound 27 (75 MHz) | S31 |
| ¹ H NMR for compound 28 (300 MHz) | S32 |
| ¹³ C NMR for compound 28 (75 MHz) | S33 |
| ¹ H NMR for compound 29 (300 MHz) | S34 |
| ¹³ C NMR for compound 29 (75 MHz) | S35 |
| ¹ H NMR for compound 30 (300 MHz) | S36 |
| ¹³ C NMR for compound 30 (75 MHz) | S37 |
| ¹ H NMR for compound 31 (300 MHz) | S38 |
| ¹³ C NMR for compound 31 (75 MHz) | S39 |
| ¹ H NMR for compound 33 (400 MHz) | S40 |
| ¹³ C NMR for compound 33 (100 MHz) | S41 |
| ¹ H NMR for compound 34 (400 MHz) | S42 |
| ¹³ C NMR for compound 34 (100 MHz) | S43 |
| ¹ H NMR for compound 36 (400 MHz) | S44 |
| ¹³ C NMR for compound 36 (100 MHz) | S45 |
| ¹ H NMR for compound 38 (300 MHz) | S46 |
| ¹³ C NMR for compound 38 (75 MHz) | S47 |
| ¹ H NMR for compound 39 (300 MHz) | S48 |
| ¹³ C NMR for compound 39 (75 MHz) | S49 |
| ¹ H NMR for compound 43 (400 MHz) | S50 |
| ¹³ C NMR for compound 43 (100 MHz) | S51 |
| ¹ H NMR for compound 51 (400 MHz) | S52 |
| ¹³ C NMR for compound 51 (100 MHz) | S53 |
| ¹ H NMR for compound 44 (300 MHz) | S54 |
| ¹³ C NMR for compound 44 (75 MHz) | S55 |
| ¹ H NMR for compound 52 (400 MHz) | S56 |
| ¹³ C NMR for compound 52 (100 MHz) | S57 |
| ¹ H NMR for compound 45 (400 MHz) | S58 |
| ¹³ C NMR for compound 45 (100 MHz) | S59 |
| ¹ H NMR for compound 53 (400 MHz) | S60 |
| ¹³ C NMR for compound 53 (100 MHz) | S61 |
| ¹ H NMR for compound 46 (300 MHz) | S62 |
| ¹³ C NMR for compound 46 (75 MHz) | S63 |
| ¹ H NMR for compound 54 (400 MHz) | S64 |
| ¹³ C NMR for compound 54 (100 MHz) | S65 |
| ¹ H NMR for compound 47 (300 MHz) | S66 |
| ¹³ C NMR for compound 47 (75 MHz) | S67 |
| ¹ H NMR for compound 55 (400 MHz) | S68 |
| ¹³ C NMR for compound 55 (100 MHz) | S69 |
| ¹ H NMR for compound 48 (300 MHz) | S70 |
| ¹³ C NMR for compound 48 (100 MHz) | S71 |
| ¹ H NMR for compound 56 (300 MHz) | S72 |
| ¹³ C NMR for compound 56 (75 MHz) | S73 |



| | |
|--|------|
| ¹ H NMR for compound 49 (300 MHz) | S74 |
| ¹³ C NMR for compound 49 (75 MHz) | S75 |
| ¹ H NMR for compound 57 (300 MHz) | S76 |
| ¹³ C NMR for compound 57 (75 MHz) | S77 |
| ¹ H NMR for compound 50 (400 MHz) | S78 |
| ¹³ C NMR for compound 50 (100 MHz) | S79 |
| ¹ H NMR for compound 58 (400 MHz) | S80 |
| ¹³ C NMR for compound 58 (100 MHz) | S81 |
| ¹ H NMR for compound 59 (400 MHz) | S82 |
| ¹ H NMR for compound 60 (400 MHz) | S83 |
| ¹³ C NMR for compound 60 (100 MHz) | S84 |
| ¹ H NMR for compound 61 (400 MHz) | S85 |
| ¹³ C NMR for compound 61 (100 MHz) | S86 |
| ¹ H NMR for compound 62 (400 MHz) | S87 |
| ¹³ C NMR for compound 62 (100 MHz) | S88 |
| 60 Cell-line assay data for compound 52 (one dose) | S89 |
| 60 Cell-line assay data for compound 55 (one dose) | S91 |
| 60 Cell-line assay data for compound 51 (five dose) | S93 |
| 60 Cell-line assay data for compound 53 (five dose) | S95 |
| 60 Cell-line assay data for compound 54 (five dose) | S97 |
| 60 Cell-line assay data for compound 56 (five dose) | S99 |
| 60 Cell-line assay data for compound 56 (five dose – replicate) | S101 |
| 60 Cell-line assay data for compound 57 (five dose) | S103 |
| 60 Cell-line assay data for compound 58 (five dose) | S105 |
| 60 Cell-line assay data for compound 60 (five dose) | S107 |





300 MHz ^1H NMR Spectrum of Compound 8





75 MHz ¹³C NMR Spectrum of Compound 8





300 MHz ^1H NMR Spectrum of Compound 9





75 MHz ^{13}C NMR Spectrum of Compound 9





300 MHz ¹H NMR Spectrum of Compound 10





75 MHz ^{13}C NMR Spectrum of Compound 10





300 MHz ¹H NMR Spectrum of Compound **11**





75 MHz ¹³C NMR Spectrum of Compound 11





300 MHz ¹H NMR Spectrum of Compound 13





75 MHz ¹³C NMR Spectrum of Compound 13





300 MHz ¹H NMR Spectrum of Compound **14**





75 MHz ¹³C NMR Spectrum of Compound 14





400 MHz ^1H NMR Spectrum of Compound 18





100 MHz ^{13}C NMR Spectrum of Compound 18





300 MHz ¹H NMR Spectrum of Compound 20





75 MHz ¹³C NMR Spectrum of Compound **20**




400 MHz ¹H NMR Spectrum of Compound 21





100 MHz ¹³C NMR Spectrum of Compound 21



300 MHz ^1H NMR Spectrum of Compound 22





75 MHz ^{13}C NMR Spectrum of Compound **22**





400 MHz ¹H NMR Spectrum of Compound 23



107\DATA\smpe8-091_2





100 MHz ¹³C NMR Spectrum of Compound 23





400 MHz ¹H NMR Spectrum of Compound 24





100 MHz ¹³C NMR Spectrum of Compound 24




400 MHz ¹H NMR Spectrum of Compound 25





100 MHz ^{13}C NMR Spectrum of Compound 25





300 MHz ¹H NMR Spectrum of Compound **27**




75 MHz ¹³C NMR Spectrum of Compound **27**




300 MHz ¹H NMR Spectrum of Compound 28





75 MHz ¹³C NMR Spectrum of Compound 28





300 MHz ^1H NMR Spectrum of Compound 29





75 MHz ¹³C NMR Spectrum of Compound **29**





300 MHz ¹H NMR Spectrum of Compound 30





75 MHz ¹³C NMR Spectrum of Compound 30





300 MHz ¹H NMR Spectrum of Compound **31**





75 MHz ¹³C NMR Spectrum of Compound 31





400 MHz ¹H NMR Spectrum of Compound 33





100 MHz ¹³C NMR Spectrum of Compound 33





400 MHz ¹H NMR Spectrum of Compound 34





100 MHz ¹³C NMR Spectrum of Compound 34





400 MHz ¹H NMR Spectrum of Compound 36





300 MHz ¹H NMR Spectrum of Compound 38





75 MHz ¹³C NMR Spectrum of Compound **38**





300 MHz ¹H NMR Spectrum of Compound 39




75 MHz ^{13}C NMR Spectrum of Compound 39




400 MHz ¹H NMR Spectrum of Compound 43




100 MHz ¹³C NMR Spectrum of Compound 43




400 MHz ¹H NMR Spectrum of Compound **51**




100 MHz ^{13}C NMR Spectrum of Compound 51





300 MHz ¹H NMR Spectrum of Compound 44





75 MHz ¹³C NMR Spectrum of Compound 44




400 MHz ^1H NMR Spectrum of Compound 52




100 MHz ^{13}C NMR Spectrum of Compound 52





400 MHz ¹H NMR Spectrum of Compound 45




100 MHz ^{13}C NMR Spectrum of Compound 45




400 MHz ^1H NMR Spectrum of Compound 53




100 MHz ¹³C NMR Spectrum of Compound 53





300 MHz ^1H NMR Spectrum of Compound 46




75 MHz ¹³C NMR Spectrum of Compound 46




400 MHz ^1H NMR Spectrum of Compound 54




100 MHz ¹³C NMR Spectrum of Compound 54





300 MHz ¹H NMR Spectrum of Compound 47





75 MHz ^{13}C NMR Spectrum of Compound **47**




400 MHz ¹H NMR Spectrum of Compound 55




100 MHz ^{13}C NMR Spectrum of Compound **55**




300 MHz ¹H NMR Spectrum of Compound 48




100 MHz ¹³C NMR Spectrum of Compound 48





300 MHz ^1H NMR Spectrum of Compound **56**




75 MHz ^{13}C NMR Spectrum of Compound **56**




300 MHz ^1H NMR Spectrum of Compound 49




75 MHz ¹³C NMR Spectrum of Compound 49




300 MHz ^1H NMR Spectrum of Compound 57




75 MHz ¹³C NMR Spectrum of Compound 57





400 MHz ¹H NMR Spectrum of Compound **50**




100 MHz ¹³C NMR Spectrum of Compound **50**




400 MHz ^1H NMR Spectrum of Compound 58




100 MHz ^{13}C NMR Spectrum of Compound 58




400 MHz ¹H NMR Spectrum of Compound **59**




400 MHz ¹H NMR Spectrum of Compound **60**




100 MHz ^{13}C NMR Spectrum of Compound **60**




400 MHz ¹H NMR Spectrum of Compound **61**



100 MHz ^{13}C NMR Spectrum of Compound 61



400 MHz ^1H NMR Spectrum of Compound **62**



100 MHz ^{13}C NMR Spectrum of Compound 62

Developmental Therapeutics Program

NSC: D-750922 / 1

Conc: 1.00E-5 Molar

Test Date: Aug 17, 2009

One Dose Bar Graph

Experiment ID: 0908OS22

Report Date: Jul 28, 2011

Panel/Cell Line


Growth Percent

Bar Graph

Compound 52


Leukemia

| | |
|-----------|-------|
| CCRF-CEM | 85.33 |
| HL-60(TB) | 69.66 |
| K-562 | 79.94 |
| MOLT-4 | 74.10 |
| RPMI-8226 | 75.01 |




Non-Small Cell Lung Cancer

| | |
|-----------|--------|
| A549/ATCC | 94.65 |
| EKVX | 107.15 |
| HOP-62 | 113.14 |
| HOP-92 | 126.63 |
| NCI-H226 | 116.82 |
| NCI-H23 | 102.66 |
| NCI-H322M | 102.34 |
| NCI-H460 | 107.68 |
| NCI-H522 | 81.49 |




Colon Cancer

| | |
|----------|--------|
| COLO 205 | 126.18 |
| HCC-2998 | 103.41 |
| HCT-116 | 84.53 |
| HCT-15 | 96.14 |
| HT29 | 74.54 |
| KM12 | 97.28 |
| SW-620 | 118.97 |




CNS Cancer

| | |
|--------|--------|
| SF-268 | 88.46 |
| SF-295 | 108.87 |
| SF-539 | 91.23 |
| SNB-19 | 106.40 |
| SNB-75 | 91.21 |
| U251 | 86.35 |




Melanoma

| | |
|------------|--------|
| LOX IMVI | 104.65 |
| MALME-3M | 114.96 |
| M14 | 106.89 |
| MDA-MB-435 | 108.97 |
| SK-MEL-2 | 112.26 |
| SK-MEL-28 | 105.71 |
| SK-MEL-5 | 99.33 |
| UACC-257 | 100.05 |
| UACC-62 | 104.40 |




Ovarian Cancer

| | |
|-------------|--------|
| IGROV1 | 63.12 |
| OVCAR-3 | 88.21 |
| OVCAR-4 | 109.83 |
| OVCAR-5 | 104.55 |
| OVCAR-8 | 108.28 |
| NCI/ADR-RES | 104.68 |
| SK-OV-3 | 115.67 |




Renal Cancer

| | |
|---------|--------|
| 786-0 | 95.95 |
| A498 | 94.70 |
| ACHN | 103.84 |
| CAKI-1 | 106.80 |
| RXF 393 | 80.69 |
| SN12C | 101.27 |
| TK-10 | 112.79 |
| UO-31 | 91.04 |




Prostate Cancer

| | |
|--------|-------|
| PC-3 | 87.56 |
| DU-145 | 91.34 |



Breast Cancer

| | |
|-----------------|--------|
| MCF7 | 102.22 |
| MDA-MB-231/ATCC | 96.59 |
| HS 578T | 64.30 |
| BT-549 | 107.66 |
| T-47D | 109.42 |
| MDA-MB-468 | 109.70 |



150 75 0.0 -75 -150
S89 Percentage Growth

Developmental Therapeutics Program

NSC: D-750922 / 1


Conc: 1.00E-5 Molar

Test Date: Aug 17, 2009

One Dose Mean Graph

Experiment ID: 0908OS22

Report Date: Jul 28, 2011



S90

Developmental Therapeutics Program

NSC: D-750921 / 1

Conc: 1.00E-5 Molar

Test Date: Aug 17, 2009

One Dose Bar Graph

Experiment ID: 0908OS22

Report Date: Jul 28, 2011

Panel/Cell Line

Growth Percent

Bar Graph

Compound 55


Leukemia

| | |
|-----------|-------|
| CCRF-CEM | 81.90 |
| HL-60(TB) | 78.18 |
| K-562 | 72.03 |
| MOLT-4 | 70.39 |
| RPMI-8226 | 65.86 |




Non-Small Cell Lung Cancer

| | |
|-----------|--------|
| A549/ATCC | 104.30 |
| EKVX | 118.02 |
| HOP-62 | 127.12 |
| HOP-92 | 107.98 |
| NCI-H226 | 120.47 |
| NCI-H23 | 100.29 |
| NCI-H322M | 167.25 |
| NCI-H460 | 105.49 |
| NCI-H522 | 72.23 |



Colon Cancer

| | |
|----------|--------|
| COLO 205 | 130.43 |
| HCC-2998 | 99.34 |
| HCT-116 | 68.50 |
| HCT-15 | 84.21 |
| HT29 | 47.92 |
| KM12 | 123.20 |
| SW-620 | 128.51 |



CNS Cancer

| | |
|--------|--------|
| SF-268 | 97.11 |
| SF-295 | 132.96 |
| SF-539 | 89.93 |
| SNB-19 | 96.37 |
| SNB-75 | 84.18 |
| U251 | 83.64 |



Melanoma

| | |
|------------|--------|
| LOX IMVI | 92.67 |
| MALME-3M | 519.50 |
| M14 | 116.63 |
| MDA-MB-435 | 119.98 |
| SK-MEL-2 | 109.07 |
| SK-MEL-28 | 118.17 |
| SK-MEL-5 | 108.21 |
| UACC-257 | 115.61 |
| UACC-62 | 90.71 |



Ovarian Cancer

| | |
|-------------|--------|
| IGROV1 | 65.34 |
| OVCAR-3 | 94.85 |
| OVCAR-4 | 108.02 |
| OVCAR-5 | 113.69 |
| OVCAR-8 | 102.76 |
| NCI/ADR-RES | 100.24 |
| SK-OV-3 | 145.26 |




Renal Cancer

| | |
|---------|--------|
| 786-0 | 69.85 |
| A498 | 140.48 |
| ACHN | 102.87 |
| CAKI-1 | 117.56 |
| RXF 393 | 88.05 |
| SN12C | 96.25 |
| UO-31 | 98.39 |



Prostate Cancer

| | |
|--------|--------|
| PC-3 | 79.00 |
| DU-145 | 105.29 |



Breast Cancer

| | |
|-----------------|--------|
| MCF7 | 102.65 |
| MDA-MB-231/ATCC | 81.28 |
| HS 578T | 82.85 |
| BT-549 | 192.56 |
| T-47D | 105.80 |
| MDA-MB-468 | 116.36 |



525 262.5 0.0 -262.5 -525

S91

Percentage Growth

Developmental Therapeutics Program

NSC: D-750921 / 1


Conc: 1.00E-5 Molar










Test Date: Aug 17, 2009

One Dose Mean Graph

Experiment ID: 0908OS22










Report Date: Jul 28, 2011














| National Cancer Institute Developmental Therapeutics Program | | NSC : D - 750920/1 | | Units :Molar | | SSPL :0GZS | | EXP. ID :0909NS78 | |
|--|------------------------|----------------------------|-----------------------|--------------|------------------------|-------------------------------|---------|-------------------|--|
| Mean Graphs | | Report Date :July 28, 2011 | | Compound 51 | | Test Date :September 28, 2009 | | | |
| Panel/Cell Line | Log ₁₀ GI50 | GI50 | Log ₁₀ TGI | TGI | Log ₁₀ LC50 | LC50 | | | |
| Leukemia | | | | | | | | | |
| CCRF-CEM | -5.08 | | > -4.00 | | > -4.00 | | > -4.00 | | |
| HL-60(TB) | -4.86 | | -4.24 | | -4.00 | | -4.00 | | |
| K-562 | -5.26 | | -4.47 | | -4.00 | | -4.00 | | |
| MOLT-4 | -5.30 | | -4.41 | | -4.00 | | -4.00 | | |
| RPMI-8226 | -5.51 | | -4.84 | | -4.00 | | -4.00 | | |
| Non-Small Cell Lung Cancer | | | | | | | | | |
| A549/ATCC | -4.88 | | -4.40 | | > -4.00 | | -4.00 | | |
| EKVX | -4.84 | | -4.24 | | > -4.00 | | -4.00 | | |
| HOP-62 | -5.21 | | -4.70 | | > -4.00 | | -4.28 | | |
| HOP-92 | -4.75 | | -4.31 | | > -4.00 | | -4.00 | | |
| NCI-H226 | -4.64 | | -4.25 | | > -4.00 | | -4.00 | | |
| NCI-H23 | -4.82 | | -4.52 | | > -4.00 | | -4.22 | | |
| NCI-H322M | -4.58 | | -4.06 | | > -4.00 | | -4.00 | | |
| NCI-H460 | -5.13 | | -4.66 | | > -4.00 | | -4.26 | | |
| NCI-H522 | -4.75 | | -4.47 | | > -4.00 | | -4.18 | | |
| Colon Cancer | | | | | | | | | |
| COLO 205 | -5.44 | | -4.96 | | > -4.00 | | -4.31 | | |
| HCC-2998 | -4.80 | | -4.43 | | > -4.00 | | -4.07 | | |
| HCT-116 | -5.11 | | -4.69 | | > -4.00 | | -4.34 | | |
| HCT-15 | -5.20 | | -4.68 | | > -4.00 | | -4.23 | | |
| HT29 | -5.71 | | -5.30 | | > -4.00 | | -4.63 | | |
| KM12 | -5.58 | | -5.19 | | > -4.00 | | -4.66 | | |
| SW-620 | -4.93 | | -4.60 | | > -4.00 | | -4.27 | | |
| CNS Cancer | | | | | | | | | |
| SF-268 | -4.83 | | -4.46 | | > -4.00 | | -4.09 | | |
| SF-295 | -5.78 | | -5.23 | | > -4.00 | | -4.41 | | |
| SF-539 | -5.38 | | -4.76 | | > -4.00 | | -4.24 | | |
| SNB-19 | -4.81 | | -4.43 | | > -4.00 | | -4.04 | | |
| SNB-75 | -5.27 | | -4.37 | | > -4.00 | | -4.00 | | |
| U251 | -5.25 | | -4.65 | | > -4.00 | | -4.20 | | |
| Melanoma | | | | | | | | | |
| LOX IMVI | -5.48 | | -4.94 | | > -4.00 | | -4.43 | | |
| MALME-3M | -4.75 | | -4.39 | | > -4.00 | | -4.04 | | |
| M14 | -4.86 | | -4.56 | | > -4.00 | | -4.25 | | |
| MDA-MB-435 | -4.76 | | -4.42 | | > -4.00 | | -4.09 | | |
| SK-MEL-2 | -4.80 | | -4.45 | | > -4.00 | | -4.09 | | |
| SK-MEL-28 | -4.79 | | -4.48 | | > -4.00 | | -4.16 | | |
| SK-MEL-5 | -5.06 | | -4.67 | | > -4.00 | | -4.31 | | |
| UACC-257 | -4.64 | | -4.26 | | > -4.00 | | -4.00 | | |
| UACC-62 | -4.89 | | -4.52 | | > -4.00 | | -4.15 | | |
| Ovarian Cancer | | | | | | | | | |
| IGROV1 | -4.84 | | -4.50 | | > -4.00 | | -4.15 | | |
| OVCAR-3 | -4.76 | | -4.47 | | > -4.00 | | -4.18 | | |
| OVCAR-4 | -4.68 | | -4.08 | | > -4.00 | | -4.00 | | |
| OVCAR-5 | -4.56 | | -4.10 | | > -4.00 | | -4.00 | | |
| OVCAR-8 | -4.60 | | -4.13 | | > -4.00 | | -4.00 | | |
| NCI/ADR-RES | -4.67 | | -4.29 | | > -4.00 | | -4.00 | | |
| SK-OV-3 | -4.64 | | > -4.00 | | > -4.00 | | -4.00 | | |
| Renal Cancer | | | | | | | | | |
| 786-O | -5.53 | | -4.92 | | > -4.00 | | -4.37 | | |
| A498 | -4.33 | | > -4.00 | | > -4.00 | | -4.00 | | |
| ACHN | -4.70 | | -4.33 | | > -4.00 | | -4.00 | | |
| CAKI-1 | -5.27 | | -4.70 | | > -4.00 | | -4.17 | | |
| RXF 393 | -5.89 | | -5.54 | | > -4.00 | | -5.18 | | |
| SN12C | -4.74 | | -4.44 | | > -4.00 | | -4.15 | | |
| TK-10 | -4.53 | | -4.10 | | > -4.00 | | -4.00 | | |
| UO-31 | -5.30 | | -4.70 | | > -4.00 | | -4.19 | | |
| Prostate Cancer | | | | | | | | | |
| PC-3 | -5.07 | | -4.25 | | > -4.00 | | -4.00 | | |
| Breast Cancer | | | | | | | | | |
| MCF7 | -4.78 | | -4.44 | | > -4.00 | | -4.10 | | |
| MDA-MB-231/ATCC | -5.00 | | -4.51 | | > -4.00 | | -4.02 | | |
| HS 578T | -5.06 | | -4.03 | | > -4.00 | | -4.00 | | |
| BT-549 | -5.30 | | -4.75 | | > -4.00 | | -4.31 | | |
| T-47D | -4.68 | | -4.23 | | > -4.00 | | -4.00 | | |
| MDA-MB-468 | -4.96 | | -4.55 | | > -4.00 | | -4.14 | | |
| MID | -4.99 | | -4.5 | | -4.15 | | | | |
| Delta | 0.9 | | 1.04 | | 1.03 | | | | |
| Range | 1.56 | | 1.54 | | 1.18 | | | | |

S94



| National Cancer Institute Developmental Therapeutics Program | | NSC : D - 750923/1 | Units :Molar | SSPL :0GZS | EXP. ID :0909NS78 | |
|--|------------------------|----------------------------|-----------------------|------------|-------------------------------|-------|
| Mean Graphs | | Report Date :July 28, 2011 | Compound 53 | | Test Date :September 28, 2009 | |
| Panel/Cell Line | Log ₁₀ GI50 | GI50 | Log ₁₀ TGI | TGI | Log ₁₀ LC50 | LC50 |
| <hr/> | | | | | | |
| Leukemia | | | | | | |
| CCRF-CEM | -5.73 | | -5.36 | | > | -4.00 |
| HL-60(TB) | -5.74 | | -5.26 | | > | -4.00 |
| K-562 | -5.62 | | | | > | -4.00 |
| MOLT-4 | -5.69 | | -5.19 | | > | -4.00 |
| RPMI-8226 | -5.69 | | -5.32 | | > | -4.00 |
| Non-Small Cell Lung Cancer | | | | | | |
| A549/ATCC | -5.67 | | -5.31 | | | -4.80 |
| EKVX | -4.93 | | -4.48 | | | -4.04 |
| HOP-62 | -5.13 | | -4.70 | | | -4.35 |
| HOP-92 | -5.47 | | -4.90 | | | -4.24 |
| NCI-H226 | -4.73 | | -4.34 | | > | -4.00 |
| NCI-H23 | -5.68 | | -5.28 | | | -4.68 |
| NCI-H322M | -4.46 | | > | -4.00 | > | -4.00 |
| NCI-H460 | -5.73 | | -5.45 | | | -5.17 |
| NCI-H522 | -5.66 | | -5.16 | | | -4.51 |
| Colon Cancer | | | | | | |
| COLO 205 | -4.92 | | -4.59 | | | -4.26 |
| HCC-2998 | -4.89 | | -4.57 | | | -4.25 |
| HCT-116 | -5.61 | | -5.22 | | | -4.69 |
| HCT-15 | -4.91 | | -4.54 | | | -4.18 |
| HT29 | -5.59 | | -4.96 | | | -4.38 |
| KM12 | -5.72 | | -5.40 | | | -5.08 |
| SW-620 | -5.52 | | -5.04 | | | -4.48 |
| CNS Cancer | | | | | | |
| SF-268 | -4.98 | | -4.59 | | | -4.20 |
| SF-295 | -5.30 | | -4.67 | | | -4.16 |
| SF-539 | -5.41 | | -4.85 | | | -4.36 |
| SNB-19 | -4.90 | | -4.58 | | | -4.26 |
| SNB-75 | -5.53 | | -4.86 | | | -4.43 |
| U251 | -5.69 | | -5.30 | | | -4.80 |
| Melanoma | | | | | | |
| LOX IMVI | -5.83 | | -5.54 | | | -5.21 |
| MALME-3M | -4.83 | | -4.44 | | | -4.05 |
| M14 | -4.89 | | -4.57 | | | -4.24 |
| MDA-MB-435 | -4.88 | | -4.54 | | | -4.20 |
| SK-MEL-2 | -4.81 | | -4.47 | | | -4.12 |
| SK-MEL-28 | -4.92 | | -4.59 | | | -4.25 |
| SK-MEL-5 | -5.15 | | -4.70 | | | -4.35 |
| UACC-257 | -4.79 | | -4.41 | | | -4.03 |
| UACC-62 | -4.85 | | -4.53 | | | -4.20 |
| Ovarian Cancer | | | | | | |
| IGROV1 | -5.53 | | -5.10 | | | -4.27 |
| OVCAR-3 | -4.92 | | -4.57 | | | -4.23 |
| OVCAR-4 | -4.90 | | -4.43 | | > | -4.00 |
| OVCAR-5 | -4.72 | | -4.15 | | > | -4.00 |
| OVCAR-8 | -5.36 | | -4.79 | | | -4.30 |
| NCI/ADR-RES | -5.41 | | -4.85 | | | -4.30 |
| SK-OV-3 | -4.77 | | -4.51 | | | -4.24 |
| Renal Cancer | | | | | | |
| 786-O | -5.48 | | -4.99 | | | -4.41 |
| A498 | -4.54 | | > | -4.00 | > | -4.00 |
| ACHN | -4.93 | | -4.58 | | > | -4.23 |
| CAKI-1 | -4.99 | | -4.63 | | | -4.27 |
| RXF 393 | -5.74 | | -5.37 | | | -5.00 |
| SN12C | -4.84 | | -4.40 | | > | -4.00 |
| TK-10 | -4.80 | | -4.49 | | | -4.17 |
| UO-31 | -5.60 | | -5.19 | | | -4.56 |
| Prostate Cancer | | | | | | |
| PC-3 | -5.29 | | -4.60 | | > | -4.00 |
| Breast Cancer | | | | | | |
| MCF7 | -4.86 | | -4.52 | | | -4.19 |
| MDA-MB-231/ATCC | -5.18 | | -4.57 | | | -4.01 |
| HS 578T | -5.06 | | > | -4.00 | > | -4.00 |
| BT-549 | -5.04 | | -4.43 | | > | -4.00 |
| T-47D | -4.91 | | -4.51 | | | -4.11 |
| MDA-MB-468 | -5.18 | | -4.70 | | | -4.34 |
| <hr/> | | | | | | |
| MID | -5.21 | | -4.76 | | -4.29 | |
| Delta | 0.65 | | 0.78 | S96 | 0.92 | |
| Range | 1.4 | | 1.54 | | 1.21 | |




Mean Graphs










Report Date :July 28, 2011

Compound **54**

Test Date :November 02, 2009












S98






| National Cancer Institute Developmental Therapeutics Program | | NSC : D - 746839/1 | Units :Molar | SSPL :0GZS | EXP. ID :0804NS72 | |
|--|------------------------|----------------------------|-----------------------|------------|---------------------------|------|
| Mean Graphs | | Report Date :July 28, 2011 | Compound 56 | | Test Date :April 14, 2008 | |
| Panel/Cell Line | Log ₁₀ GI50 | GI50 | Log ₁₀ TGI | TGI | Log ₁₀ LC50 | LC50 |
| Leukemia | | | | | | |
| CCRF-CEM | -6.92 | | -5.36 | | > -4.00 | |
| HL-60(TB) | -7.33 | | -5.84 | | -4.43 | |
| K-562 | -6.58 | | -5.16 | | > -4.00 | |
| MOLT-4 | -7.47 | | -6.61 | | > -4.00 | |
| RPMI-8226 | < -8.00 | | -6.46 | | > -4.00 | |
| SR | -6.54 | | -5.39 | | > -4.00 | |
| Non-Small Cell Lung Cancer | | | | | | |
| A549/ATCC | -6.02 | | -5.05 | | -4.41 | |
| EKVX | -6.01 | | -4.99 | | -4.44 | |
| HOP-62 | -6.54 | | -5.63 | | -4.97 | |
| HOP-92 | -5.64 | | -5.18 | | -4.30 | |
| NCI-H226 | -5.91 | | -5.50 | | -5.09 | |
| NCI-H23 | -5.82 | | -5.35 | | -4.58 | |
| NCI-H322M | -5.49 | | -4.86 | | -4.36 | |
| NCI-H460 | -6.47 | | -5.04 | | -4.19 | |
| NCI-H522 | -5.79 | | -4.96 | | -4.28 | |
| Colon Cancer | | | | | | |
| COLO 205 | -6.24 | | -5.65 | | -5.14 | |
| HCT-116 | -6.22 | | -5.63 | | -5.20 | |
| HCT-15 | -5.95 | | -5.53 | | -5.10 | |
| HT29 | -6.19 | | -5.50 | | -4.87 | |
| KM12 | -5.93 | | -5.54 | | -5.15 | |
| SW-620 | -6.48 | | -5.80 | | -5.29 | |
| CNS Cancer | | | | | | |
| SF-268 | -5.87 | | -5.29 | | -4.37 | |
| SF-295 | -7.62 | | -6.71 | | -4.57 | |
| SF-539 | -7.41 | | -5.78 | | -5.16 | |
| SNB-19 | -5.93 | | -4.94 | | -4.42 | |
| SNB-75 | -6.91 | | -5.20 | | -4.47 | |
| U251 | -7.12 | | -5.66 | | -5.23 | |
| Melanoma | | | | | | |
| LOX IMVI | -6.40 | | -5.73 | | -5.33 | |
| MALME-3M | -5.71 | | -5.29 | | -4.51 | |
| M14 | -5.96 | | -5.49 | | -5.03 | |
| MDA-MB-435 | -6.12 | | -5.30 | | -4.46 | |
| SK-MEL-2 | -5.16 | | -4.65 | | -4.25 | |
| SK-MEL-28 | -6.00 | | -5.56 | | -5.12 | |
| SK-MEL-5 | -6.02 | | -5.64 | | -5.27 | |
| UACC-257 | -5.12 | | -4.63 | | -4.21 | |
| UACC-62 | -6.69 | | -6.10 | | -5.13 | |
| Ovarian Cancer | | | | | | |
| IGROV1 | -5.87 | | -5.18 | | -4.39 | |
| OVCAR-3 | -5.84 | | -5.39 | | -4.81 | |
| OVCAR-4 | -5.69 | | -4.89 | | -4.32 | |
| OVCAR-5 | -5.60 | | -4.88 | | -4.34 | |
| OVCAR-8 | -5.60 | | -4.91 | | -4.29 | |
| NCI/ADR-RES | -5.59 | | -4.99 | | -4.23 | |
| SK-OV-3 | -5.86 | | -4.97 | | -4.45 | |
| Renal Cancer | | | | | | |
| 786-C | -7.50 | | -5.84 | | -4.81 | |
| A498 | -6.93 | | -5.61 | | -4.92 | |
| ACHN | -5.85 | | -4.92 | | -4.44 | |
| CAKI-1 | -5.77 | | -5.17 | | -4.41 | |
| RXF 393 | < -8.00 | | -7.26 | | -5.36 | |
| SN12C | -5.82 | | -5.44 | | -5.07 | |
| TK-10 | -5.66 | | -5.07 | | -4.38 | |
| UO-31 | -6.75 | | -4.99 | | -4.43 | |
| Prostate Cancer | | | | | | |
| PC-3 | -6.43 | | -5.28 | | -4.38 | |
| DU-145 | -5.70 | | -5.11 | | -4.11 | |
| Breast Cancer | | | | | | |
| MCF7 | -6.51 | | -5.60 | | -4.98 | |
| MDA-MB-231/ATCC | -5.92 | | -5.54 | | -5.15 | |
| HS 578T | -7.43 | | -6.48 | | -4.58 | |
| BT-549 | -6.56 | | -4.92 | | -4.16 | |
| T-47D | -5.86 | | -5.37 | | -4.59 | |
| MDA-MB-468 | -5.98 | | -5.52 | | -5.07 | |
| MID | -6.28 | | -5.43 | | -4.63 | |
| Delta | 1.72 | | 1.83 | | 0.73 | |
| Range | 2.88 | | 2.63 | | 1.36 | |










S100



| National Cancer Institute Developmental Therapeutics Program | | NSC : D - 746839/1 | Units :Molar | SSPL :0GZS | EXP. ID :0806RS26 | |
|--|------------------------|----------------------------|-----------------------|--------------------|------------------------|--------------------------|
| Mean Graphs | | Report Date :July 28, 2011 | | Compound 56 | | Test Date :June 02, 2008 |
| Panel/Cell Line | Log ₁₀ GI50 | GI50 | Log ₁₀ TGI | TGI | Log ₁₀ LC50 | LC50 |
| <hr/> | | | | | | |
| Leukemia | | | | | | |
| CCRF-CEM | -7.29 | | -6.47 | | -5.23 | |
| HL-60(TB) | -7.49 | | -5.96 | | -5.09 | |
| K-562 | -6.75 | | -5.73 | | -4.69 | |
| MOLT-4 | -7.56 | | -7.09 | | -6.18 | |
| RPMI-8226 | -7.98 | | -7.41 | | -6.33 | |
| SR | -7.23 | | -6.11 | | -5.23 | |
| <hr/> | | | | | | |
| Non-Small Cell Lung Cancer | | | | | | |
| A549/ATCC | -6.26 | | -4.97 | | -4.39 | |
| EKVX | -6.43 | | -5.10 | | -4.49 | |
| HOP-62 | -6.32 | | -5.09 | | -4.52 | |
| HOP-92 | -5.90 | | -5.21 | | -4.47 | |
| NCI-H226 | -5.23 | | -4.67 | | -4.26 | |
| NCI-H23 | -5.95 | | -5.46 | | -4.92 | |
| NCI-H322M | -5.47 | | -4.85 | | -4.43 | |
| NCI-H460 | -6.49 | | -5.52 | | -4.53 | |
| NCI-H522 | -5.72 | | -5.07 | | -4.44 | |
| <hr/> | | | | | | |
| Colon Cancer | | | | | | |
| COLO 205 | -6.36 | | -5.78 | | -5.39 | |
| HCC-2998 | -6.07 | | -5.53 | | -5.03 | |
| HCT-116 | -6.29 | | -5.68 | | -5.27 | |
| HCT-15 | -6.27 | | -5.62 | | -5.16 | |
| HT29 | -5.91 | | -5.31 | | -4.56 | |
| KM12 | -6.08 | | -5.67 | | -5.32 | |
| SW-620 | -6.72 | | -5.92 | | -5.46 | |
| <hr/> | | | | | | |
| CNS Cancer | | | | | | |
| SF-268 | -5.92 | | -5.45 | | -4.95 | |
| SF-295 | -7.68 | | -7.06 | | -6.16 | |
| SF-539 | -7.28 | | -5.81 | | -5.28 | |
| SNB-19 | -5.54 | | -4.75 | | -4.37 | |
| SNB-75 | -7.63 | | -6.28 | | -4.72 | |
| U251 | -7.17 | | -5.58 | | -4.97 | |
| <hr/> | | | | | | |
| Melanoma | | | | | | |
| LOX IMVI | -6.28 | | -5.72 | | -5.35 | |
| MALME-3M | -6.06 | | -5.49 | | -4.94 | |
| M14 | -6.35 | | -5.46 | | -4.73 | |
| MDA-MB-435 | -6.10 | | -5.58 | | -5.13 | |
| SK-MEL-2 | -5.97 | | -5.37 | | -4.64 | |
| SK-MEL-28 | -6.41 | | -5.58 | | -5.10 | |
| SK-MEL-5 | -6.39 | | -5.77 | | -5.35 | |
| UACC-257 | -5.20 | | -4.67 | | -4.30 | |
| UACC-62 | -6.75 | | -6.11 | | -5.24 | |
| <hr/> | | | | | | |
| Ovarian Cancer | | | | | | |
| IGROV1 | -5.68 | | -4.96 | | -4.43 | |
| OVCAR-3 | -5.96 | | -5.60 | | -5.24 | |
| OVCAR-4 | -5.58 | | -4.72 | | -4.20 | |
| OVCAR-5 | -5.84 | | -5.08 | | -4.53 | |
| OVCAR-8 | -5.55 | | -4.90 | | -4.32 | |
| NCI/ADR-RES | -5.87 | | -5.25 | | -4.61 | |
| SK-OV-3 | -6.02 | | -4.83 | | -4.42 | |
| <hr/> | | | | | | |
| Renal Cancer | | | | | | |
| 786-0 | -7.47 | | -6.60 | | -5.60 | |
| A498 | -7.49 | | -6.45 | | -5.39 | |
| ACHN | -5.75 | | -4.96 | | -4.48 | |
| RXF 393 | -8.00 | | -7.65 | | -7.08 | |
| SN12C | -5.83 | | -5.53 | | -5.22 | |
| TK-10 | -5.73 | | -5.05 | | -4.49 | |
| UO-31 | -7.24 | | -4.94 | | -4.44 | |
| <hr/> | | | | | | |
| Prostate Cancer | | | | | | |
| PC-3 | -6.71 | | -5.55 | | -4.76 | |
| DU-145 | -5.90 | | -4.93 | | -4.45 | |
| <hr/> | | | | | | |
| Breast Cancer | | | | | | |
| MCF7 | -6.71 | | -5.46 | | -4.53 | |
| MDA-MB-231/ATCC | -6.10 | | -5.56 | | -5.09 | |
| HS 578T | -7.60 | | -6.11 | | -4.57 | |
| BT-549 | -6.62 | | -5.36 | | -4.57 | |
| T-47D | -5.85 | | -5.15 | | -4.40 | |
| MDA-MB-468 | -5.96 | | -5.50 | | -5.04 | |
| <hr/> | | | | | | |
| <hr/> | | | | | | |
| MID | -6.41 | | -5.58 | | -4.92 | |
| Delta | 1.59 | | 2.07 | | 2.16 | |
| Range | 2.8 | | 2.98 | | 2.88 | |












S102






| National Cancer Institute Developmental Therapeutics Program | | NSC : D - 749943/1 | | Units :Molar | | SSPL :0GZS | | EXP. ID :0905NS16 | |
|--|------------------------|----------------------------|-----------------------|--------------|------------------------|-------------------------|--|-------------------|--|
| Mean Graphs | | Report Date :July 28, 2011 | | Compound 57 | | Test Date :May 11, 2009 | | | |
| Panel/Cell Line | Log ₁₀ GI50 | GI50 | Log ₁₀ TGI | TGI | Log ₁₀ LC50 | LC50 | | | |
| Leukemia | | | | | | | | | |
| CCRF-CEM | -5.85 | | -4.86 | | > | -4.30 | | | |
| HL-60(TB) | -5.82 | | -5.18 | | | -4.52 | | | |
| K-562 | -5.92 | | -5.39 | | | -4.64 | | | |
| MOLT-4 | -6.05 | | -5.56 | | | -4.48 | | | |
| RPMI-8226 | -6.75 | | -5.81 | | | -4.30 | | | |
| SR | -5.99 | | -5.50 | | > | -4.65 | | | |
| Non-Small Cell Lung Cancer | | | | | | | | | |
| A549/ATCC | -5.61 | | -4.98 | | | -4.55 | | | |
| EKVX | -5.68 | | -4.97 | | | -4.49 | | | |
| HOP-62 | -6.08 | | -5.55 | | | -4.96 | | | |
| NCI-H226 | -5.23 | | -4.91 | | | -4.59 | | | |
| NCI-H23 | -5.25 | | -4.91 | | | -4.57 | | | |
| NCI-H322M | -5.17 | | -4.73 | | > | -4.30 | | | |
| NCI-H460 | -5.88 | | -5.28 | | | -4.79 | | | |
| NCI-H522 | -5.35 | | -4.91 | | | -4.49 | | | |
| Colon Cancer | | | | | | | | | |
| COLO 205 | -6.25 | | -5.93 | | | -5.62 | | | |
| HCC-2998 | -5.77 | | -5.00 | | | -4.65 | | | |
| HCT-116 | -5.49 | | -5.01 | | | -4.66 | | | |
| HCT-15 | -5.89 | | -5.22 | | | -4.75 | | | |
| HT29 | -6.40 | | -5.58 | | | -4.88 | | | |
| KM12 | -5.87 | | -5.22 | | | -4.73 | | | |
| SW-620 | -5.91 | | -5.40 | | | -4.85 | | | |
| CNS Cancer | | | | | | | | | |
| SF-268 | -5.61 | | -5.03 | | | -4.67 | | | |
| SF-295 | -6.73 | | -6.06 | | | -5.41 | | | |
| SF-539 | -6.81 | | -5.96 | | | -5.12 | | | |
| SNB-19 | -5.41 | | -4.85 | | | -4.38 | | | |
| SNB-75 | -5.44 | | -4.93 | | | -4.52 | | | |
| U251 | -6.38 | | -5.11 | | | -4.71 | | | |
| Melanoma | | | | | | | | | |
| LOX IMVI | -5.85 | | -5.30 | | | -4.80 | | | |
| MALME-3M | -5.29 | | -4.87 | | | -4.44 | | | |
| MDA-MB-435 | -5.37 | | -4.93 | | | -4.54 | | | |
| SK-MEL-2 | -5.27 | | -4.92 | | | -4.56 | | | |
| SK-MEL-28 | -5.37 | | -4.97 | | | -4.64 | | | |
| SK-MEL-5 | -6.02 | | -5.63 | | | -5.16 | | | |
| UACC-257 | -5.17 | | -4.85 | | | -4.53 | | | |
| UACC-62 | -5.97 | | -5.42 | | | -4.86 | | | |
| Ovarian Cancer | | | | | | | | | |
| IGROV1 | -5.24 | | -4.87 | | | -4.51 | | | |
| OVCAR-3 | -5.44 | | -4.98 | | | -4.63 | | | |
| OVCAR-4 | -5.24 | | -4.89 | | | -4.54 | | | |
| OVCAR-8 | -5.26 | | -4.88 | | | -4.51 | | | |
| SK-OV-3 | -5.49 | | -4.74 | | > | -4.30 | | | |
| Renal Cancer | | | | | | | | | |
| 786-0 | -6.91 | | -6.44 | | | -5.38 | | | |
| A498 | -5.74 | | -5.08 | | | -4.66 | | | |
| ACHN | -5.56 | | -5.03 | | | -4.67 | | | |
| CAKI-1 | -5.95 | | -5.18 | | | -4.67 | | | |
| RXF 393 | -7.05 | | -6.52 | | > | -4.30 | | | |
| SN12C | -5.23 | | -4.88 | | | -4.54 | | | |
| TK-10 | -5.15 | | -4.82 | | | -4.49 | | | |
| UO-31 | -5.95 | | -5.12 | | | -4.66 | | | |
| Prostate Cancer | | | | | | | | | |
| PC-3 | -6.13 | | -5.00 | | | -4.43 | | | |
| DU-145 | -5.42 | | -4.99 | | | -4.64 | | | |
| Breast Cancer | | | | | | | | | |
| MCF7 | -5.99 | | -5.23 | | | -4.76 | | | |
| MDA-MB-231/ATCC | -5.69 | | -5.11 | | | -4.71 | | | |
| BT-549 | -5.98 | | -5.04 | | | -4.60 | | | |
| T-47D | -5.64 | | -5.04 | | | -4.63 | | | |
| MID | | | | | | | | | |
| Delta | 1.27 | | 1.32 | | | 0.94 | | | |
| Range | 1.9 | | 1.79 | | | 1.32 | | | |










S104



| National Cancer Institute Developmental Therapeutics Program | | NSC : D - 758339/1 | | Units :Molar | | SSPL :0GZS | | EXP. ID :1106NS64 | |
|--|------------------------|----------------------------|-----------------------|--------------|------------------------|--------------------------|--|-------------------|--|
| Mean Graphs | | Report Date :July 28, 2011 | | Compound 58 | | Test Date :June 13, 2011 | | | |
| Panel/Cell Line | Log ₁₀ GI50 | GI50 | Log ₁₀ TGI | TGI | Log ₁₀ LC50 | LC50 | | | |
| ----- | | | | | | | | | |
| Leukemia | | | | | | | | | |
| CCRF-CEM | -5.99 | | > -4.00 | | > -4.00 | | | | |
| HL-60(TB) | -6.18 | | -4.47 | | >> -4.00 | | | | |
| K-562 | -5.60 | | -4.54 | | >>> -4.00 | | | | |
| MOLT-4 | -6.40 | | > -4.00 | | >>> -4.00 | | | | |
| RPMI-8226 | -6.32 | | > -4.00 | | >>> -4.00 | | | | |
| ----- | | | | | | | | | |
| Non-Small Cell Lung Cancer | | | | | | | | | |
| A549/ATCC | -6.01 | | -4.57 | | > -4.00 | | | | |
| EKVX | -5.35 | | -4.08 | | > -4.00 | | | | |
| HOP-62 | -6.27 | | -4.96 | | >> -4.19 | | | | |
| HOP-92 | -5.59 | | -4.78 | | >>> -4.34 | | | | |
| NCI-H226 | -4.84 | | -4.52 | | >>> -4.19 | | | | |
| NCI-H23 | -5.38 | | -4.61 | | >>> -4.13 | | | | |
| NCI-H322M | -4.65 | | -4.04 | | > -4.00 | | | | |
| NCI-H460 | -6.06 | | > -4.00 | | > -4.00 | | | | |
| NCI-H522 | -4.98 | | -4.55 | | >>> -4.11 | | | | |
| ----- | | | | | | | | | |
| Colon Cancer | | | | | | | | | |
| COLO 205 | -5.45 | | -4.85 | | >>> -4.18 | | | | |
| HCC-2998 | -4.97 | | -4.56 | | >>> -4.15 | | | | |
| HCT-116 | -5.46 | | -4.74 | | >>> -4.34 | | | | |
| HCT-15 | -5.87 | | -4.99 | | >>> -4.09 | | | | |
| HT29 | -5.69 | | -4.72 | | > -4.00 | | | | |
| KM12 | -5.37 | | -4.67 | | >>> -4.24 | | | | |
| SW-620 | -5.71 | | -4.87 | | >>> -4.17 | | | | |
| ----- | | | | | | | | | |
| CNS Cancer | | | | | | | | | |
| SF-268 | -5.39 | | -4.68 | | >>> -4.26 | | | | |
| SF-295 | -6.82 | | -6.30 | | >>> -4.47 | | | | |
| SF-539 | -6.85 | | -4.90 | | > -4.00 | | | | |
| SNB-19 | -4.95 | | -4.53 | | >>> -4.11 | | | | |
| SNB-75 | -6.58 | | -4.83 | | > -4.00 | | | | |
| U251 | -6.56 | | -4.81 | | >>> -4.27 | | | | |
| ----- | | | | | | | | | |
| Melanoma | | | | | | | | | |
| LOX IMVI | -6.26 | | -5.52 | | >>> -4.74 | | | | |
| MALME-3M | -4.93 | | -4.17 | | >>> -4.00 | | | | |
| M14 | -6.16 | | -4.66 | | >>> -4.00 | | | | |
| MDA-MB-435 | -5.86 | | -4.25 | | >>> -4.00 | | | | |
| SK-MEL-2 | -4.75 | | -4.18 | | >>> -4.00 | | | | |
| SK-MEL-28 | -5.92 | | -4.51 | | >>> -4.00 | | | | |
| SK-MEL-5 | -5.65 | | -4.91 | | >>> -4.39 | | | | |
| UACC-257 | -5.46 | | -4.40 | | > -4.00 | | | | |
| UACC-62 | -6.26 | | -4.97 | | >>> -4.24 | | | | |
| ----- | | | | | | | | | |
| Ovarian Cancer | | | | | | | | | |
| IGROV1 | -4.80 | | > -4.00 | | > -4.00 | | | | |
| OVCAR-3 | -4.90 | | -4.56 | | >>> -4.22 | | | | |
| OVCAR-4 | -5.14 | | -4.35 | | > -4.00 | | | | |
| OVCAR-5 | -5.18 | | -4.38 | | >>> -4.00 | | | | |
| OVCAR-8 | -4.96 | | -4.53 | | >>> -4.11 | | | | |
| NCI/ADR-RES | -5.09 | | -4.53 | | >>> -4.02 | | | | |
| SK-OV-3 | -4.71 | | -4.09 | | > -4.00 | | | | |
| ----- | | | | | | | | | |
| Renal Cancer | | | | | | | | | |
| 786-O | -6.80 | | -6.04 | | >>> -5.08 | | | | |
| A498 | -6.03 | | -4.71 | | >>> -4.30 | | | | |
| ACHN | -5.65 | | -4.30 | | >>> -4.00 | | | | |
| CAKI-1 | -6.09 | | -4.82 | | >>> -4.00 | | | | |
| RXF 393 | -7.18 | | -6.45 | | >>> -5.57 | | | | |
| SN12C | -5.18 | | -4.65 | | >>> -4.23 | | | | |
| TK-10 | -4.80 | | -4.38 | | > -4.00 | | | | |
| UO-31 | -6.30 | | -4.82 | | >>> -4.03 | | | | |
| ----- | | | | | | | | | |
| Prostate Cancer | | | | | | | | | |
| PC-3 | -6.04 | | > -4.00 | | > -4.00 | | | | |
| DU-145 | -5.42 | | -4.70 | | >>> -4.28 | | | | |
| ----- | | | | | | | | | |
| Breast Cancer | | | | | | | | | |
| MDA-MB-231/ATCC | -5.79 | | -4.84 | | >>> -4.24 | | | | |
| HS 578T | -6.26 | | > -4.00 | | > -4.00 | | | | |
| BT-549 | -5.86 | | -4.75 | | >>> -4.30 | | | | |
| T-47D | -4.94 | | -4.31 | | > -4.00 | | | | |
| MDA-MB-468 | -5.75 | | -4.91 | | >>> -4.31 | | | | |
| ----- | | | | | | | | | |
| MID | | | | | | | | | |
| Delta | -5.68 | | -4.62 | | -4.16 | | | | |
| Range | 1.5 | | 1.83 | | 1.41 | | | | |
| | 2.53 | | 2.45 | | 1.57 | | | | |

S106





| National Cancer Institute Developmental Therapeutics Program | | NSC : D - 758340/1 | | Units :Molar | | SSPL :0GZS | | EXP. ID :1106NS64 | |
|--|------------------------|----------------------------|-----------------------|--------------------|------------------------|--------------------------|--|-------------------|--|
| Mean Graphs | | Report Date :July 28, 2011 | | Compound 60 | | Test Date :June 13, 2011 | | | |
| Panel/Cell Line | Log ₁₀ GI50 | GI50 | Log ₁₀ TGI | TGI | Log ₁₀ LC50 | LC50 | | | |
| Leukemia | | | | | | | | | |
| CCRF-CEM | -5.36 | | > -4.00 | | > -4.00 | | | | |
| HL-60(TB) | -5.45 | | > -4.22 | | > -4.00 | | | | |
| K-562 | -5.36 | | > -4.32 | | > -4.00 | | | | |
| MOLT-4 | -5.55 | | > -4.88 | | > -4.00 | | | | |
| RPMI-8226 | -5.93 | | > -4.00 | | > -4.00 | | | | |
| Non-Small Cell Lung Cancer | | | | | | | | | |
| A549/ATCC | -5.11 | | > -4.00 | | > -4.00 | | | | |
| EKVX | -5.26 | | > -4.00 | | > -4.00 | | | | |
| HOP-62 | -5.31 | | > -4.00 | | > -4.00 | | | | |
| HOP-92 | -4.80 | | > -4.00 | | > -4.00 | | | | |
| NCI-H226 | -4.55 | | > -4.00 | | > -4.00 | | | | |
| NCI-H23 | -4.96 | | > -4.00 | | > -4.00 | | | | |
| NCI-H322M | -4.05 | | > -4.00 | | > -4.00 | | | | |
| NCI-H460 | -5.23 | | > -4.00 | | > -4.00 | | | | |
| NCI-H522 | -4.74 | | > -4.00 | | > -4.00 | | | | |
| Colon Cancer | | | | | | | | | |
| COLO 205 | -5.46 | | > -5.03 | | > -4.29 | | | | |
| HCC-2998 | -4.91 | | > -4.00 | | > -4.00 | | | | |
| HCT-116 | -5.18 | | > -4.45 | | > -4.00 | | | | |
| HCT-15 | -5.48 | | > -4.29 | | > -4.00 | | | | |
| HT29 | -5.36 | | > -4.00 | | > -4.00 | | | | |
| KM12 | -5.10 | | > -4.12 | | > -4.00 | | | | |
| SW-620 | -4.99 | | > -4.35 | | > -4.00 | | | | |
| CNS Cancer | | | | | | | | | |
| SF-268 | -4.96 | | > -4.07 | | > -4.00 | | | | |
| SF-295 | -5.92 | | > -5.36 | | > -4.00 | | | | |
| SF-539 | -6.05 | | > -4.89 | | > -4.00 | | | | |
| SNB-19 | -4.78 | | > -4.00 | | > -4.00 | | | | |
| SNB-75 | -5.79 | | > -4.00 | | > -4.00 | | | | |
| U251 | -5.76 | | > -4.22 | | > -4.00 | | | | |
| Melanoma | | | | | | | | | |
| LOX IMVI | -5.40 | | > -4.80 | | > -4.35 | | | | |
| MALME-3M | -5.10 | | > -4.02 | | > -4.00 | | | | |
| M14 | -4.95 | | > -4.19 | | > -4.00 | | | | |
| MDA-MB-435 | -5.17 | | > -4.16 | | > -4.00 | | | | |
| SK-MEL-2 | -4.89 | | > -4.00 | | > -4.00 | | | | |
| SK-MEL-28 | -5.53 | | > -4.00 | | > -4.00 | | | | |
| SK-MEL-5 | -5.14 | | > -4.64 | | > -4.23 | | | | |
| UACC-257 | -5.40 | | > -4.31 | | > -4.00 | | | | |
| UACC-62 | -5.39 | | > -4.00 | | > -4.00 | | | | |
| Ovarian Cancer | | | | | | | | | |
| IGROV1 | -5.01 | | > -4.00 | | > -4.00 | | | | |
| OVCAR-3 | -4.56 | | > -4.00 | | > -4.00 | | | | |
| OVCAR-4 | -5.16 | | > -4.00 | | > -4.00 | | | | |
| OVCAR-5 | -4.93 | | > -4.00 | | > -4.00 | | | | |
| OVCAR-8 | -4.77 | | > -4.21 | | > -4.00 | | | | |
| NCI/ADR-RES | -4.67 | | > -4.00 | | > -4.00 | | | | |
| Sk-OV-3 | -4.38 | | > -4.00 | | > -4.00 | | | | |
| Renal Cancer | | | | | | | | | |
| 786-O | -5.99 | | > -4.00 | | > -4.00 | | | | |
| A498 | -5.12 | | > -4.00 | | > -4.00 | | | | |
| ACHN | -5.10 | | > -4.00 | | > -4.00 | | | | |
| CAKI-1 | -5.40 | | > -4.00 | | > -4.00 | | | | |
| RXF 393 | -6.51 | | > -5.88 | | > -4.91 | | | | |
| SN12C | -4.83 | | > -4.00 | | > -4.00 | | | | |
| TK-10 | -4.60 | | > -4.00 | | > -4.00 | | | | |
| UO-31 | -5.39 | | > -4.00 | | > -4.00 | | | | |
| Prostate Cancer | | | | | | | | | |
| PC-3 | -5.09 | | > -4.00 | | > -4.00 | | | | |
| DU-145 | -4.87 | | > -4.00 | | > -4.00 | | | | |
| Breast Cancer | | | | | | | | | |
| MDA-MB-231/ATCC | -5.47 | | > -4.80 | | > -4.00 | | | | |
| HS 578T | -5.76 | | > -4.00 | | > -4.00 | | | | |
| BT-549 | -5.41 | | > -4.20 | | > -4.00 | | | | |
| T-47D | -4.87 | | > -4.00 | | > -4.00 | | | | |
| MDA-MB-468 | -5.31 | | > -4.33 | | > -4.00 | | | | |
| MID | | | | | | | | | |
| Delta | -5.2 | | -4.2 | S108 | -4.03 | | | | |
| Range | 1.31 | | 1.68 | | 0.88 | | | | |
| | 2.46 | | 1.88 | | 0.91 | | | | |